Is a privately held biopharmaceutical company devoted to the development and commercialization of novel proprietary vaccines and diagnostic tools for prevention of cancer
– Jon Amund Eriksen, CEO Hubro Bioscience
The global cancer immunotherapy market was valued at $57,256.2 million in 2017 and is expected to reach $166,714.5 million by 2025, registering a CAGR of 14.42% during the period, 2018-2025 [1].
The lead candidate vaccine FMPV3 targets shared tumour specific neoantigens is expected to enter clinical phase in 2025. The targets are frameshifts mutations greatly associated with hereditary colorectal-, endometrial- and gastric-cancer as well as other hereditary MSI cancers.
Hollingsworth, R. E. & Jansen, K. NPJ vaccines 4, 7, doi:10.1038/s41541-019-0103-y (2019).
The Company has a highly experienced international management and operational team, an extensive network of industrial and academic partners to optimise and leverage the development of its novel technology.
Founder and Chairman Of the Board of Directors / CEO Jon Amund Eriksen has established multiple cancer immunology companies and is a highly respected individual in the field of cancer vaccines.
Stimulating the immune system to prevent cancer and improve the quality of the lives of high-risk families
Contact us
CEO Jon Amund Eriksen: jaeriksen@hubrobio.com